참고문헌
- A.E. Mathew, M.R. Mejillano, J.P. Nath, R.H. Himes and V.J. Stella, Synthesis and evaluation of some water-soluble prodrugs and derivatives of taxol with antitumor activity, J. Med. Chem., 35(1), 145-151 (1992) https://doi.org/10.1021/jm00079a019
- P.M. Chaudhary and I.B. Robinson, Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell, 66, 85-94 (1991) https://doi.org/10.1016/0092-8674(91)90141-K
- J.A. Endicott and V. Ling, The biochemistry of P-glycoprotein- mediated multidrug resistance, Annu. Rev. Biochem., 58, 137-171 (1989) https://doi.org/10.1146/annurev.bi.58.070189.001033
- A. Rahman, K.R. Korzekwa, J. Grogan, F.J. Gonzalez and J.W. Harris, Selective biotransformation of taxol to 6-hydroxytaxol by human cytochrome P450 2C8., Cancer Res., 54, 5543-5548 (1994)
- D.S. Sonnichsen, Q. Liu, E.G, Schuetz, J.D. Schuetz, A. Pappo and M.V. ReIling, Variability in human cytochrome P450 paclitaxel metabolism., J. Pharmacol. Exp. Ther., 275, 566-571 (1995)
- T. Walle, Short communication, Taxol metabolism in rat hepatocytes. Biochem. Pharmacol., 46(9), 1661-1664 (1993) https://doi.org/10.1016/0006-2952(93)90336-U
- D.S. Sonnichsen and M.V. ReIling, Clinical Pharmacokinetics of Paclitaxel, Clin. Phannacokinet., 27(4), 256-269 (1994) https://doi.org/10.2165/00003088-199427040-00002
- G.A. Fisher and B.I. Sikic, Clinical studies with modulators of multidrug resistance. Hematol. Oncol. Clin. North Am., 9(2), 363-382 (1995)
- E. Hofsli and J.N. Meyer, Reversal of multidrug resistance by lipophilic drugs, Cancer Res., 50, 3997-4002 (1990)
- L.J. Bain, J.B. McLanchlan and G.A. LeBanc, Structureactivity relationship for xenobiotic transport substrates and inhibitory ligands of p-glycoprotein, Enviromental Health Perspectives, 105(8), 812-818 (1997) https://doi.org/10.2307/3433698
- T. Cresteil, B. Monsarrat, P. Alvinerid, J.M. Treluyer, I. Vieira and M. Wright. Taxol metabolism by human liver microsomes, identification of cytochrome P450 isozymes involved in its biotransformation, Cancer Res., 54, 386-395 (1994)
- J.W. Harris, A. Rahman, B.R. Kim, F.P. Guengerich and J.M. Collins, Metabolism of taxol by human hepatic microsomes and liver slices, participation of cytochrome P450 3A4 and an unknown P450 enzyme, Cancer Res., 54, 4026-4031 (1994)
- E.J. Wang, K. Lew, C.N. Casciano, R.P. Clement and W.W. Johnson, Interaction of common azole antifungals with P glycoprotein, Antimicrab. Agents Chemother, 46(1), 160-165 (2002) https://doi.org/10.1128/AAC.46.1.160-165.2002
- E.J. Wang, C.N. Casciano, R.P. Clement and W.W Johnson, HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein, Pharm. Res., 18, 800-806 (2001) https://doi.org/10.1023/A:1011036428972
- I. Hsu, S.A. Spinler and N.E. Johnson, Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia, Ann. Pharmacother., 29, 743-759 (1995) https://doi.org/10.1177/106002809502907-818
- A. Bohme, A. Ganser and D. Hoelzer, Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult, ALL. Ann. Hematol., 71, 311-312 (1995) https://doi.org/10.1007/BF01697985
- S. Gupta, J. Kim and S. Gollapudi, Reversal of daunorubicin resistance in P388/ADR cells by itraconazole, J. Clin. Investig., 87, 1467-1469 (1991) https://doi.org/10.1172/JCI115154
- G. Vreugdenhil, J.M. Raemaekers, B.J. Dijke, van and B.E. Pauw, de Itraconazole and multidrug resistance, possible effects on remission rate and disease-free survival in acute leukemia, Ann. Hematol., 67, 107-109 (1993) https://doi.org/10.1007/BF01701730
- K.M. Kaukonen, K.T. Olkkola and P.J. Neuvonen, Itraconazole increases plasma concentrations of quinidine, Clin. Pharmacol. Ther., 62, 510-517 (1997) https://doi.org/10.1016/S0009-9236(97)90046-1
- K.M. Jalava, J. Partanen and P.J. Neuvonen, Itraconazole decreases renal clearance of digoxin, Ther. Drug Monit., 19, 609-613 (1997) https://doi.org/10.1097/00007691-199712000-00001
- J.M. Poirier and G. Cheymol, Optimisation of itraconazole therapy using target drug concentrations, Clin. Pharmacokinet., 35, 461-473 (1998) https://doi.org/10.2165/00003088-199835060-00004
- D. Debruyne, Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses, Clin. Pharmacokinet., 33, 52-77 (1997) https://doi.org/10.2165/00003088-199733010-00005
- K. Venkatakrishnan, L.L. von Moltke and D.J. Greenblatt, Effects of the antifungal agents on oxidative drug metabolism, clinical relevance, Clin. Pharmacokinet., 38, 111-180 (2000) https://doi.org/10.2165/00003088-200038020-00002
- J. Combalbert, I. Fabre and G. Fabre, et al., Metabolism of cyclosprrine A, IV : purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450A gene subfamily, Drug Metab. Disprs., 17, 197-207 (1989)
- T. Kronbach, V. Fischer and U.A. Meyer, Cyclosprrine metabolism in human liver, identification of a cytochrome P450 gene family as the major cyclosporine with other drugs, Clin. Pharmacol. Ther., 43, 630-635 (1988) https://doi.org/10.1038/clpt.1988.87
- J.C. Korars, P. Schmiedlin-Ren, J.D. Cchuetz, C. Fang and P.B. Watkins, Identification of rifampin-inducible P450A4 (CYP3A4) in human small bowel enterocytes, J. Clin. Invest., 90, 1871-1878 (1992) https://doi.org/10.1172/JCI116064
- J.C. Korars, W.M. Awni, P.M. Merion and P.B. Watkins, Firstpass metabolism of cyclosporin by the gut, Lancet, 338, 1488-1490 (1991) https://doi.org/10.1016/0140-6736(91)92302-I
- D.Y. Gomez, V.J. Wacher, S.J. Tomlanovich, M.F. Hebert and L.Z. Benet, The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine, Clin. Pharmacol. Ther., 58(1), 15-19 (1995) https://doi.org/10.1016/0009-9236(95)90067-5
- K.M. Kaukonen, K.T. Olkkola and P.J. Neuvonen, Itraconazole increases plasma concentrations of quinidine, Clin. Pharmacol. Ther., 62(5), 510-517 (1997) https://doi.org/10.1016/S0009-9236(97)90046-1
- N. Manrin, J. Catalin, M.F. Blachon and A. Durand, Assay of paclitaxel (Taxol) in plasma and urine by High Performance Liquid Chromatogrphy, J. Chromato. B., 709, 281-288 (1998) https://doi.org/10.1016/S0378-4347(98)00060-7
- H. Mase, M. Hiraoka and F. Suzuki, Determination of New Anticancer Drug, Paclitaxel, in Biological Fluids by High Performance Liquid Chromatography, Yakugaku. Zasshi., 114(5), 351-355 (1994) https://doi.org/10.1248/yakushi1947.114.5_351
- K. Yamaoka, Y. Tanigawara, T. Nakagawa and T. Uno, A pharmacokinetics analysis program for microcomputer, J. Pham. Dyn., 4, 79-883 (1981)